170 related articles for article (PubMed ID: 9284529)
1. Papillomavirus-like particles and HPV vaccine development.
Schiller JT; Lowy DR
Semin Cancer Biol; 1996 Dec; 7(6):373-82. PubMed ID: 9284529
[TBL] [Abstract][Full Text] [Related]
2. Cellular immune responses to human papillomavirus (HPV)-16 L1 in healthy volunteers immunized with recombinant HPV-16 L1 virus-like particles.
Pinto LA; Edwards J; Castle PE; Harro CD; Lowy DR; Schiller JT; Wallace D; Kopp W; Adelsberger JW; Baseler MW; Berzofsky JA; Hildesheim A
J Infect Dis; 2003 Jul; 188(2):327-38. PubMed ID: 12854090
[TBL] [Abstract][Full Text] [Related]
3. Mucosal vaccination with a recombinant Salmonella typhimurium expressing human papillomavirus type 16 (HPV16) L1 virus-like particles (VLPs) or HPV16 VLPs purified from insect cells inhibits the growth of HPV16-expressing tumor cells in mice.
Revaz V; Benyacoub J; Kast WM; Schiller JT; De Grandi P; Nardelli-Haefliger D
Virology; 2001 Jan; 279(1):354-60. PubMed ID: 11145916
[TBL] [Abstract][Full Text] [Related]
4. Human papillomavirus vaccines.
Breitburd F; Coursaget P
Semin Cancer Biol; 1999 Dec; 9(6):431-44. PubMed ID: 10712890
[TBL] [Abstract][Full Text] [Related]
5. Vaccines for the prevention of human papillomavirus and associated gynecologic diseases: a review.
Ault KA
Obstet Gynecol Surv; 2006 Jun; 61(6 Suppl 1):S26-31. PubMed ID: 16729901
[TBL] [Abstract][Full Text] [Related]
6. Preventative and therapeutic vaccines for cervical cancer.
Roden R; Wu TC
Expert Rev Vaccines; 2003 Aug; 2(4):495-516. PubMed ID: 14711335
[TBL] [Abstract][Full Text] [Related]
7. Chapter 12: Prophylactic HPV vaccines: underlying mechanisms.
Stanley M; Lowy DR; Frazer I
Vaccine; 2006 Aug; 24 Suppl 3():S3/106-13. PubMed ID: 16949996
[TBL] [Abstract][Full Text] [Related]
8. [Human papillomavirus prophylactic vaccines: stakes and perspectives].
Hantz S; Alain S; Denis F
Gynecol Obstet Fertil; 2006; 34(7-8):647-55. PubMed ID: 16807045
[TBL] [Abstract][Full Text] [Related]
9. Neutralization of human papillomavirus type 11 (HPV-11) by serum from women vaccinated with yeast-derived HPV-11 L1 virus-like particles: correlation with competitive radioimmunoassay titer.
Brown DR; Bryan JT; Schroeder JM; Robinson TS; Fife KH; Wheeler CM; Barr E; Smith PR; Chiacchierini L; DiCello A; Jansen KU
J Infect Dis; 2001 Nov; 184(9):1183-6. PubMed ID: 11598842
[TBL] [Abstract][Full Text] [Related]
10. Minor capsid protein of human genital papillomaviruses contains subdominant, cross-neutralizing epitopes.
Roden RB; Yutzy WH; Fallon R; Inglis S; Lowy DR; Schiller JT
Virology; 2000 May; 270(2):254-7. PubMed ID: 10792983
[TBL] [Abstract][Full Text] [Related]
11. Prophylactic HPV vaccines: reducing the burden of HPV-related diseases.
Villa LL
Vaccine; 2006 Mar; 24 Suppl 1():S23-8. PubMed ID: 16194583
[TBL] [Abstract][Full Text] [Related]
12. Effect of preexisting neutralizing antibodies on the anti-tumor immune response induced by chimeric human papillomavirus virus-like particle vaccines.
Da Silva DM; Pastrana DV; Schiller JT; Kast WM
Virology; 2001 Nov; 290(2):350-60. PubMed ID: 11883199
[TBL] [Abstract][Full Text] [Related]
13. Papillomavirus-like particle vaccines for cervical cancer.
Schiller JT
Mol Med Today; 1999 May; 5(5):209-15. PubMed ID: 10322313
[TBL] [Abstract][Full Text] [Related]
14. Human papillomavirus vaccines.
Stanley MA
Rev Med Virol; 2006; 16(3):139-49. PubMed ID: 16710836
[TBL] [Abstract][Full Text] [Related]
15. Human papillomavirus types 6 and 11 have antigenically distinct strongly immunogenic conformationally dependent neutralizing epitopes.
Christensen ND; Kirnbauer R; Schiller JT; Ghim SJ; Schlegel R; Jenson AB; Kreider JW
Virology; 1994 Nov; 205(1):329-35. PubMed ID: 7526536
[TBL] [Abstract][Full Text] [Related]
16. Papillomavirus virus-like particles as vehicles for the delivery of epitopes or genes.
Xu YF; Zhang YQ; Xu XM; Song GX
Arch Virol; 2006 Nov; 151(11):2133-48. PubMed ID: 16791442
[TBL] [Abstract][Full Text] [Related]
17. HPV vaccine MedImmune/GlaxoSmithKline.
Billich A
Curr Opin Investig Drugs; 2003 Feb; 4(2):210-3. PubMed ID: 12669384
[TBL] [Abstract][Full Text] [Related]
18. A phase I study to evaluate a human papillomavirus (HPV) type 18 L1 VLP vaccine.
Ault KA; Giuliano AR; Edwards RP; Tamms G; Kim LL; Smith JF; Jansen KU; Allende M; Taddeo FJ; Skulsky D; Barr E
Vaccine; 2004 Aug; 22(23-24):3004-7. PubMed ID: 15297048
[TBL] [Abstract][Full Text] [Related]
19. Preclinical model to test human papillomavirus virus (HPV) capsid vaccines in vivo using infectious HPV/cottontail rabbit papillomavirus chimeric papillomavirus particles.
Mejia AF; Culp TD; Cladel NM; Balogh KK; Budgeon LR; Buck CB; Christensen ND
J Virol; 2006 Dec; 80(24):12393-7. PubMed ID: 17005666
[TBL] [Abstract][Full Text] [Related]
20. Strategies for the prevention of cervical cancer by human papillomavirus vaccination.
Williamson AL; Passmore JA; Rybicki EP
Best Pract Res Clin Obstet Gynaecol; 2005 Aug; 19(4):531-44. PubMed ID: 16150392
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
